BioPharmaSpec is a global Contract Research Organization specializing in the structural and physicochemical characterization and testing of biopharmaceuticals. From laboratories in the United Kingdom, USA and Europe (Germany, Italy and Lithuania) BioPharmaSpec supports the biopharmaceutical industry in the cost-effective characterization of therapeutic products.
The technical expertise at BioPharmaSpec includes the structural characterization and biophysical/ physicochemical analysis of recombinant biopharmaceuticals such as biosimilars and biobetters, monoclonal antibodies, Antibody Drug Conjugates (ADCs), gene therapy products (i.e. AAV- based therapies), peptides, oligonucleotides and many more product types, with a focus on discovery, early and pre-clinical phases.
BioPharmaSpec ‘s founders, Prof Howard Morris (founder of the M-Scan group of companies) and Dr Andrew Reason (previously Group Manager of the European M-Scan laboratories), and their team of scientists originally pioneered the now well-accepted strategies of mass spectrometric peptide mapping, the use of mass spectrometry in disulfide bridge assignment and the discovery and characterization of glycosylation in natural and recombinant proteins.
